/VRCA
VRCA Stock - Verrica Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$7.82-3.58%
$0.29 (-3.58%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.60
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+117.4%upside
Target: $17.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VRCA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.74 – $7.90
TARGET (TP)$17.00
STOP LOSS$7.19
RISK/REWARD1:14.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.50
52W High$9.82
52W Low$3.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.57M | $5.12M | $9.03M | $12.00M | N/A |
| Gross Profit | $4.83M | $4.38M | $8.31M | $11.53M | $-229,000 |
| Gross Margin | 63.8% | 85.4% | 92.0% | 96.1% | N/A |
| Operating Income | $-65,919,000 | $-65,759,000 | $-21,296,000 | $-30,908,000 | $-40,181,000 |
| Net Income | $-76,579,000 | $-66,995,000 | $-24,487,000 | $-35,080,000 | $-45,497,000 |
| Net Margin | -1012.1% | -1307.5% | -271.1% | -292.3% | N/A |
| EPS | $-14.78 | $-14.78 | $-7.17 | $-12.97 | $-17.08 |
Company Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$9
Average Target
↑ 11.9% Upside
Now
$4
Low
$9
Average
$11
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 6th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| November 5th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | - |
| July 25th 2023 | Needham | Upgrade | Buy | $10 |
| March 22nd 2023 | Jefferies | Initiation | Buy | $10 |
| February 13th 2023 | RBC Capital Mkts | Upgrade | Outperform | $11← $4 |
| May 25th 2022 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $16 |
Earnings History & Surprises
VRCABeat Rate
78%
Last 18 quarters
Avg Surprise
+32.6%
EPS vs Estimate
Beats / Misses
14/3
1 met exactly
Latest EPS
$0.13
Q4 2025
EPS Surprise History
Q1 24
-2.1%
$-0.48vs$-0.47
Q2 24
+29.6%
$-0.38vs$-0.54
Q3 24
+27.9%
$-0.31vs$-0.43
Q4 24
-32.4%
$-0.49vs$-0.37
Q1 25
+4.0%
$-0.24vs$-0.25
Q2 25
+28.6%
$-1.00vs$-1.40
Q3 25
+102.9%
$0.02vs$-0.70
Q4 25
+111.4%
$0.13vs$-1.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.14 | $0.13 | +111.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.70 | $0.02 | +102.9% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-1.40 | $-1.00 | +28.6% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $-0.37 | $-0.49 | -32.4% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.43 | $-0.31 | +27.9% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.54 | $-0.38 | +29.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.47 | $-0.48 | -2.1% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.22 | $-0.32 | -45.5% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.20 | $-0.11 | +45.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.11 | $0.07 | +163.6% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.32 | $-0.32 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $-0.54 | $-0.25 | +53.7% | ✓ BEAT |
Q1 2022 | Mar 2, 2022 | $-0.48 | $-0.35 | +27.1% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.49 | $-0.40 | +18.4% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Latest News
Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target
📈 PositiveBenzinga•Dec 18, 2025, 12:39 PM
Verrica Pharmaceuticals Announces $4.24M Private Placement With Common Stock, Pre-Funded Warrants And Series C Warrants
📈 PositiveBenzinga•Nov 24, 2025, 04:28 PM
Verrica Pharmaceuticals shares are trading higher after the company announced a $50 million private placement to retire debt and extend its cash runway.
📈 PositiveBenzinga•Nov 24, 2025, 01:01 PM
Verrica Pharmaceuticals Announces $50M Private Placement Financing To Retire Debt And Extend Cash Runway
📈 PositiveBenzinga•Nov 24, 2025, 01:01 PM
Verrica Pharmaceuticals Q3 Adj. EPS $0.13 Beats $(0.68) Estimate, Sales $14.344M Beat $5.843M Estimate
📈 PositiveBenzinga•Nov 14, 2025, 09:11 PM
Verrica Pharmaceuticals Gets European Medicines Agency's Committee's Positive Feedback To File Marketing Authorization Application For YCANTH To Treat Molluscum Contagiosum
📈 PositiveBenzinga•Oct 20, 2025, 08:09 PM
Verrica Pharmaceuticals To Present Phase 2 Data On VP-315 For Basal Cell Carcinoma At SITC 2025 Annual Meeting
📈 PositiveBenzinga•Oct 7, 2025, 08:08 PM
Verrica Pharma's Development Partner, Torii Pharma, Receives Approval From Japanese MHLW For YCANTH For Treatment Of Molluscum Contagiosum
📈 PositiveBenzinga•Sep 19, 2025, 12:12 PM
Verrica Pharmaceuticals shares are trading higher after development partner Torii Pharmaceutical received Japan approval for YCANTH to treat molluscum contagiosum, triggering a $10M payment to Verrica.
📈 PositiveBenzinga•Sep 19, 2025, 12:04 PM
Verrica Pharmaceuticals Development Partner, Torii Pharmaceutical, Receives Japan Approval For YCANTH In Treatment Of Molluscum Contagiosum; Approval Triggers $10M Payment To Verrica
📈 PositiveBenzinga•Sep 19, 2025, 12:03 PM
Verrica Posts Profit in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 02:23 AM
Frequently Asked Questions about VRCA
What is VRCA's current stock price?
Verrica Pharmaceuticals Inc. (VRCA) is currently trading at $7.82 per share. The stock has moved -3.58% today.
What is the analyst price target for VRCA?
The average analyst price target for VRCA is $17.00, based on 1 analyst.
What sector is Verrica Pharmaceuticals Inc. in?
Verrica Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VRCA's market cap?
Verrica Pharmaceuticals Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does VRCA pay dividends?
No, Verrica Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
Explore stocks similar to VRCA for comparison